Who is Clay Siegall and What Does He Do?
Clay Siegall Ph.D. is the co-founder, CEO and chairman of Seattle Genetics. Seattle Genetics has been in business since 1998. Seattle Genetics was founded within a vision of innovative biotechnological research and a passion for helping patients. It has several licenses including with Pfizer. To date, it has generated more than $1.2 billion through very inclusive and diverse funding. Seattle Genetics has also achieved what they have by collaborating with other biotechnological companies.
During the 1980’s and early-to-middle 1990’s, Dr. Siegall worked for various institutions including the National Institutes of Health and the National Cancer Institute. He has won numerous awards, including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. He earned his Ph.D. in Genetics from George Washington University.
Media Who has Featured Siegall
The Seaport World Trade Center’s Pegs Boston did an interview with Dr. Siegall in May 2015 about the future that he envisions for Seattle Genetics and the ADCETRIS (ADC) drug, which is designed to help prevent relapse complications that often arise post-transplant. At the time that the interview went to print, Seattle Genetics was still waiting for the FDA’s approval for ADC. However, Seattle Genetics had just established a couple of other drugs, SGN-CD33A and SGN-CD19A. The former is designed to target leukimia cells and the latter is designed to stabilize the bloodstream to enable the cytotoxic agents to be flushed out.
In September 2016, Hackryonm reported that Seattle Genetics did receive the stamp of approval from the FDA in 2011. This occurred after Seattle Genetics had established various cancer antibodies that not only treat the disease on the surface, they also work as therapies. However, Seattle Genetics does not limit itself to treating cancer. They are also very passionately dedicated to treating a variety of other autoimmune diseases such as lupus.